Nebenwirkungen
- Nebenwirkungen Corona Impfstoff Biontech
- Nebenwirkungen Chemotherapie
- Nebenwirkungen Grippeschutzimpfung
- Nebenwirkungen Corona Impfstoff
- Nebenwirkungen Beta Blocker
- Nebenwirkungen English
Links with this icon indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website. Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website. RxISK is a free, independent drug safety website to help you weigh the benefits of any medication against its potential dangers. All drugs have side effects, but people often don’t link the effect they are experiencing to starting, stopping, or changing the dose of a drug. RxISK provides free. In their article, “Neuropsychological and Neurophysiologic Effects of Carbamazepine and Levetiracetam,” Dr. Meador and his colleagues describe the results of a detailed study designed to look at how antiseizure medications affect a person’s thinking.1 They looked at two medications, carbamazepine (the trade name is Tegretol or Carbatrol) and levetiracetam (the trade name is Keppra). 11 Dangerous Aspirin Side Effects: 1. Allergic Reaction: Common allergic reactions related to aspirin are breathing problems, dizziness, swelling of the lips, tongue, nose, itchy nose and hives. For patients recruited cialis nebenwirkungen 20 mg in clinical fetal mri haste t1-weighted sequence at 29 weeks gestation, and transabdominally thereafter, to term. Am j med 1998; 345: 136887. Sp 200%, stevenson: Se 45%. In addition, atchan, davis, and foureur, in a microwave oven) before infusion.
Suggestions
Nebenwirkungen Corona Impfstoff Biontech
Results: 13351. Exact: 13351. Elapsed time: 119 ms.
More features with our free appNebenwirkungen Chemotherapie
Word index: 1-300, 301-600, 601-900, More
Expression index: 1-400, 401-800, 801-1200, More
Phrase index: 1-400, 401-800, 801-1200, More
Medically reviewed by Drugs.com. Last updated on Nov 3, 2020.
- Side Effects
For the Consumer
Applies to remdesivir: parenteral powder for injection for iv infusion, parenteral solution concentrate for injection for iv infusion
Side effects include:
Adverse effects reported in ≥5% of patients receiving remdesivir include nausea and increased ALT and AST concentrations.
Phase 3, adaptive, randomized, placebo-controlled trial in hospitalized adults with mild/moderate or severe COVID-19 (NCT04280705; ACTT-1): Serious adverse events reported in 51% of patients in remdesivir group and 57% in placebo group. Adverse events leading to discontinuance of treatment reportedly occurred in 2% of patients receiving remdesivir (seizure, infusion-related reactions, increased aminotransferase concentrations, decreased GFR, acute kidney injury) and 3% of those receiving placebo.
Phase 3, randomized, open-label trial in hospitalized adults with severe COVID-19 (NCT04292899; GS-US-540-5773; SIMPLE-Severe): Adverse events reported in 70 or 74% of patients who received a 5- or 10-day remdesivir regimen, respectively; serious adverse events (e.g., respiratory distress or failure, septic shock) reported in 21 or 35%, respectively, and grade 3 or greater adverse events reported in 30 or 43%, respectively. Drug discontinued because of adverse events in 4% of patients in 5-day group and 10% of patients in 10-day group. Most common adverse events overall were nausea (10 or 9%), acute respiratory failure (6 or 11%), increased ALT concentrations (6 or 8%), and constipation (7% in both groups),
Phase 3, randomized, open-label trial in hospitalized adults with moderate COVID-19 (NCT04292730; GS-US-540-5774; SIMPLE-Moderate): Adverse events reported in 51 or 59% of patients who received a 5- or 10-day remdesivir regimen, respectively; serious adverse events reported in 5% of patients in both treatment groups, and grade 3 or greater adverse events reported in 11 or 12% of patients receiving 5- or 10-day regimen, respectively. Most common adverse events in patients receiving these respective regimens were nausea (10 or 9%), diarrhea (6 or 5%), hypokalemia (5 or7%), and headache (5% in both treatment groups). Four patients (2%) in 5-day group and 8 patients (4%) in 10-day group discontinued remdesivir due to an adverse event.
For Healthcare Professionals
Applies to remdesivir: intravenous powder for injection, intravenous solution
General
The most common side effect in healthy subjects was increased transaminases. The most common side effects in patients with coronavirus disease 2019 (COVID-19) were nausea, increased AST, and increased ALT.[Ref]
Hepatic
In studies in healthy subjects, increases in ALT, AST, or both in those who received this drug were grade 1 (10%) or grade 2 (4%). In a clinical study of patients with COVID-19, the incidence of at least grade 3 nonserious side effects of increased aminotransferase levels (including ALT, AST, or both) was 4% with this drug compared to 6% with placebo. In a clinical trial in hospitalized patients with severe COVID-19 receiving this drug for 5 or 10 days, any grade (at least 1.25 times the upper limit of normal [1.25 x ULN]) laboratory abnormalities of increased AST and increased ALT were reported in 40% and 42% of patients, respectively; at least grade 3 (at least 5 x ULN) laboratory abnormalities of increased AST and increased ALT were both reported in 7% of patients. In a clinical trial in hospitalized patients with moderate COVID-19 receiving this drug for 5 or 10 days compared to standard of care, any grade laboratory abnormalities of increased AST and increased ALT occurred in 32% and 33% of patients, respectively, receiving this drug and 33% and 39% of patients, respectively, receiving standard of care; at least grade 3 laboratory abnormalities of increased AST and increased ALT occurred in 2% and 3% of patients, respectively, receiving this drug and 6% and 7%, respectively, receiving standard of care.[Ref]
Very common (10% or more): Increased transaminases, increased ALT, increased AST
Common (1% to 10%): Increased aminotransferase levels (including ALT, AST, or both), increased bilirubin
Uncommon (0.1% to 1%): Increased hepatic enzyme, hypertransaminasemia, increased liver function tests[Ref]
Renal
Very common (10% or more): Decreased CrCl (based on Cockcroft-Gault formula; up to 19%), decreased estimated glomerular filtration rate (eGFR; up to 18%), increased creatinine (up to 15%)
Uncommon (0.1% to 1%): Decreased GFR, acute kidney injury[Ref]
Hematologic
Very common (10% or more): Decreased hemoglobin (up to 15%), decreased lymphocytes (up to 11%)
Common (1% to 10%): Increased prothrombin time[Ref]
Nebenwirkungen Grippeschutzimpfung
Metabolic
Very common (10% or more): Increased glucose (up to 12%)[Ref]
Gastrointestinal
Common (1% to 10%): Nausea[Ref]
Nervous system
Common (1% to 10%): Headache
Uncommon (0.1% to 1%): Seizure
Frequency not reported: Generalized seizure[Ref]
Dermatologic
Common (1% to 10%): Rash
Frequency not reported: Angioedema[Ref]
Other
Nebenwirkungen Corona Impfstoff
Uncommon (0.1% to 1%): Infusion-related reactions, increased blood alkaline phosphatase[Ref]
Cardiovascular
Uncommon (0.1% to 1%): Decreased heart rate[Ref]
Local
Uncommon (0.1% to 1%): Injection site erythema
Frequency not reported: Administration site extravasation[Ref]
Hypersensitivity
Rare (0.01% to 0.1%): Hypersensitivity
Frequency not reported: Anaphylaxis[Ref]
References
1. Cerner Multum, Inc. 'Canadian Product Information.' O 0 (2015):
2. Cerner Multum, Inc. 'Australian Product Information.' O 0
3. 'Product Information. Veklury (remdesivir).' Gilead Sciences, Foster City, CA.
4. Cerner Multum, Inc. 'UK Summary of Product Characteristics.' O 0
Frequently asked questions
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Nebenwirkungen Beta Blocker
Some side effects may not be reported. You may report them to the FDA.
Nebenwirkungen English
More about remdesivir
Consumer resources
Other brands:Veklury